Dilemma of HBsAg seroconversion in chronic hepatitis B infection
Seyed Moayed Alavian 1*, Seyed Mohammad Miri 1

1 Baqiyatallah Research Center for Gastroenterology and Liver Disease, Tehran, IR Iran

ARTICLE INFO

Article Type: Editorial

Article history:
Received: 01 Jan 2011
Revised: 04 Jan 2011
Accepted: 07 Jan 2011

Keywords:
Hepatitis B infection
HBsAg
Seroconversion
Occult hepatitis B
Iran

Implication for health policy/practice/research/medical education:
This editorial has been written to emphasize one of the most important articles published in 11(2) and draw reader’s attention towards it. Clinicians in the fields of infectious diseases and internal medicine should be aware of managing chronic carriers of HBV who experience negative seroconversion.

Please cite this paper as:
Alavian SM, Miri SM. Dilemma of HBsAg seroconversion in chronic hepatitis B infection. Hepat Mon. 2011;11(2):67-68.

The prevalence of occult hepatitis B (OHB) infection in HBsAg--seroconverted patients has not yet been reported in the medical literatures. Due to the unknown outcomes of these patients who lost HBsAg and not seroconverted to anti-HBs with no detectable HBV DNA, Taheri et al. (1) determined the efficacy of HBV vaccine in such patients during 8 years of follow-up. Undoubtedly, this unique study opens a new window toward HBsAg seroclearance. Their results strengthen the hypothesis that chronic HBsAg-positive cases who have lost HBsAg and are negative for serum HBV DNA in their sera may still have occult HBV infection. Several factors influence the natural history of HBV infection, including the age at which the infection is acquired; viral characteristics, such as HBV genotype, viral mutations, and level of HBV replication, host factors, such as gender, age, and immune status; and exogenous factors, such as concomitant infection with other hepatotropic viruses or alcohol consumption. Prior to implementation of the national vaccination program for Iranian children, the main risk factor for acquiring HBV infection was perinatal infection from HBsAg-positive mothers to their infants during delivery (2-4). Most patients with chronic HBV infection are inactive carriers, and there are an estimated 300 million inactive carriers worldwide. The diagnosis of inactive HBsAg carrier is based on the absence of HBeAg, the presence of anti-HBe, undetectable or low levels of HBV DNA in PCR-based assays, repeatedly normal ALT levels, minimal or no necroinflammation, slight fibrosis, and normal histology by biopsy (5). According to published findings and due to variations in viral load, more than one HBV DNA test is required to make the diagnosis (6).

One of the principal outcomes of follow up of HBV inactive carriers is seronversion which means becoming HBsAg negative and developing anti-HBs. There is a significant difference in HBsAg seroclearance rate between different studies and ethnicities. This difference could be owing to the difference in the occurrence time of HBV infection. In communities with more adolescent infections, such as western countries, the incidence of delayed HBsAg clearance ranges from 1% to 2% per year; while a lower rates, from 0.05% to 0.8% per year, are reported in endemic areas, where HBV infection is primarily acquired perinatally or in early childhood (7).
Although no Iranian report has been published, we estimate the incidence to be less than 0.5% per year (unpublished data).

With regard to the meaning of seroconversion, HBsAg seroclearance has been defined as the loss of serum HBsAg on 2 occasions at least 6 months apart, maintained to the study conclusion (8, 9). HBsAg seroclearance, which is associated with HBV DNA levels at baseline and follow-up, is one of the most important predictors of seroclearance. Higher HBV viral loads effect lower HBsAg seroclearance rates (P<0.001). A spontaneous decrease in follow-up HBV-DNA levels (>3 logs) was associated significantly with seroclearance, showed an adjusted odds ratio of 4.17 (95% confidence interval, 2.55-6.82). Among those who experience seroclearance, 95.8% have undetectable HBV DNA levels before seroclearance (10). Further, the clearance of HBsAg has been reported to be higher in women than in men and in older carriers (7). Although the prognosis is improved by the loss of HBsAg—because the liver disease is usually inactive and nonprogressive—HBsAg clearance does not prevent the development of decompensation or Hepatocellular carcinoma in patients who have already become cirrhotic (11). Occult hepatitis B (OBH) infection is an outcome of inactive carriers with HBV infection; thus, we should consider this issue in all cases of seroconversion, especially for patients in our region (12-15). According to the previous report about the effectiveness of HBV vaccine in anti HBcAb positive cases, we found that 20% of these cases had no respond to the vaccine. Among these patients, patients with a positive history of HBsAg vaccination in people with positive anti-HBc but negative HBsAg results of Taheri et al. Thanks to the main message of this conclusion (8, 9). HBsAg seroclearance, which is associated with HBV DNA levels at baseline and follow-up might be the most important predictors of HBsAg seroclearance (10). Also, the authors did not gather sufficient data regarding the exact time of HBV detection in their subjects (1). And the third limitation is related to not forgetting one of the possible explanations of HBsAg negativity when there is low titer of HBsAg in the serum.

References
1. Taheri H, Hasanjani Roushan MR, Soleimani Amiri MJ, Pouralijan M, Bijani A. Efficacy of HBV vaccine in subjects who lost HBsAg during follow-up. Hepat Mon. 2011;11(2):177-20.
2. Hajiani E, Hashemi S, Masjedizadeh A. Seroepidemiology of Hepatitis B Virus Infection in Khuzestan Province, Southwest of Iran. Hepat Mon. 2009;9(3):34-8.
3. Saleh-Gargari S, Hantoushzadeh S, Zendehehd N, Jamal A, Aghdam H. The Association of Maternal HBsAg Carrier Status and Perinatal Outcome. Hepat Mon. 2009;9(1):180-4.
4. Uyar Y, Cebel C, Balci A. Seroreversion of Hepatitis B Virus among Pregnant Women in Northern Turkey. Hepat Mon. 2009;9(2):446-9.
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2009;49(5):1225-41.
6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507-39.
7. Sharma SK, Saini N, Chwla Y. Hepatitis B virus: inactive carriers. Virol J. 2005;2:82.
8. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45(3):1177-92.
9. Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology. 2009;49(6):3859-67.
10. Liu J, Yang HJ, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139(2):474-82.
11. Feld JJ, Ayers M, El-Ashry D, Mazzulli T, Tellier R, Heathcote EJ. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2007;46(4):1057-70.
12. Hollinger FB, Habibollahi P, Daneshmand A, Alavian SM. Occult Hepatitis B Infection in Chronic Hemodialysis Patients: Current Concepts and Strategy. Hepat Mon. 2010;10(3):399-204.
13. Habibollahi P, Safari S, Daryani NE, Alavian SM. Occult hepatitis B infection and its possible impact on chronic hepatitis C virus infection. Saudi J Gastroenterol. 2009;15(4):220-4.
14. Honarkar Z, Alavian SM, Samiei S, Saedi K, Zali MR. Occult hepatitis B among chronic liver disease patients. Saudi Med J. 2005;26(4):601-6.
15. Alavian SM. Occult hepatitis b and hemodialysis patients need increased precautions with the interpretation of results. Ther Apher Dial. 2010;14(6):569-70.
16. Kahmar A, Keshvari M, Kashani AH, Alavian SM. Predicting response to HBV vaccination in people with positive anti-HBc but negative HBsAg and anti-HBs. Hum Vaccin. 2008;4(5):379-83.